Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The US FDA has requested the manufacturers of rosiglitazone [Avandia] and pioglitazone [Actos] to add a boxed warning

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      FDA.Statement of Andrew C. von Eschenbach, M.D. Commissioner of Food and Drugs: Food and Drug Administration: before the Committee on Oversight and Government Reform, United States House of Representatives. Internet Document: [17 pages], 6 Jun 2007. Available from: URL: http://www.oversight.house.gov

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    The US FDA has requested the manufacturers of rosiglitazone [Avandia] and pioglitazone [Actos] to add a boxed warning. React. Wkly. 1157, 2 (2007). https://doi.org/10.2165/00128415-200711570-00004

    Download citation

    Keywords

    • Public Health
    • Heart Failure
    • Congestive Heart Failure
    • Rosiglitazone
    • Pioglitazone